A phase 2, 16 week, multicenter, randomized, double blind placebo controlled, parallel group proof of concept study evaluating the efficacy and safety of PF-04383119 [tanezumab] for the treatment of pain associated with interstitial cystitis.

Trial Profile

A phase 2, 16 week, multicenter, randomized, double blind placebo controlled, parallel group proof of concept study evaluating the efficacy and safety of PF-04383119 [tanezumab] for the treatment of pain associated with interstitial cystitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2015

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Pelvic pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 19 May 2015 Pooled analysis (1035, 1010, 1019) results presented at the 110th Annual Meeting of the American Urological Association.
    • 17 Mar 2011 Primary endpoint 'Numerical Rating Scale' has been met according to results published in the Journal of Urology.
    • 17 Mar 2011 Results published in the Journal of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top